BiomX (PHGE) entered into definitive agreements in connection with a private investment in public equity financing for expected gross proceeds of approximately $3M, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. In the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of $1,000 per share, together with warrants w

BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the

Meihua International Medical Technologies (MHUA) shares plunged 43% after the company reported late

BiomX Inc (PHGE) progresses in clinical trials for BX004 and BX011, despite facing financial constraints and a temporary FDA hold on US trials.